TORONTO, ONTARIO / ACCESSWIRE / June 23, 2020 / Nighthawk Gold Corp. ("Nighthawk" or the "Company") (TSX:NHK)(OTCQX:MIMZF) is pleased to announce the results from the 2019 regional exploration program on its 100% owned Indin Lake Gold Property in the Northwest Territories, Canada. Field activities were carried out from June to early September 2019 and included detailed bedrock mapping and sampling of several key target areas (Figure 1).

A total of 1,485 grab and channel samples were collected to follow-up on some of the areas highlighted by the 2018 regional program (see press release dated February 19, 2019), and to continue exploring for new opportunities throughout the Indin Lake Gold Property. Field work has resulted in the discovery of new areas of mineralization and the expansion of several strategic gold occurrences. Regional diamond drilling in 2019 was limited to the Treasure Island Gold Project ("Treasure Island") where 19 holes were successfully completed, further advancing this well mineralized target area.

Dr. Michael Byron, President & CEO commented, "Nighthawk acquired Colomac and consolidated approximately 95% of the Indin Lake Greenstone Belt, including all of its historical gold mines, deposits, and showings to execute on the enormous untapped potential of this land package. Colomac is a unique brownfield asset with incredible promise that was largely overlooked until its affinity to one of the world's richest gold deposits was recognized by Nighthawk in 2012. As Colomac continues to progress and reveal its multi-million-ounce growth trajectory, the value of the fertile gold camp that it resides within also grows in prominence, and we control it all. The Indin Lake camp resembles many of Canada's prolific Archean gold camps except for its vastly unexplored state, and therein lies its value proposition; a juvenile gold camp with its full discovery potential yet to be realized."

Highlights

Treasure Island 2019 Drill Program – All 19 holes intersected gold mineralization highlighted by hole T19-11 which intersected 12.70 m of 8.51 grams per tonne gold ("gpt" "Au"), including 7.30 m of 14.06 gpt Au. A 200-metre wide panel of mineralization has been traced continuously over 750 metres along strike from surface to upwards of 200 metres vertical depth where it remains open.
High-grade gold at Andy Lake Project ("Andy Lake") – Channel and grab samples returned up to 42.80 gpt Au from mineralized shears.
New high-grade gold mineralization at Barker-Vidie showing – Grab samples returned up to 13.65 gpt Au – high-grade zone extended to 300 m along strike.
Zone 24 surface showing – Grab samples returned up to 8.83 gpt Au taken from surface quartz veins.
New surface showings at Fishhook Gold Project ("Fishhook") – Grab samples returned up to 6.25 gpt Au from host silicate and oxide facies iron formation.

2019 Regional Exploration Results

The Indin Lake Greenstone Belt is home to several gold deposits and high-grade showings presenting a range of mineralization styles that are hosted in brittle regimes. These typomorphic features, being characteristic of most productive high-profile Archean gold camps, highlight the perspectivity of the Indin Lake Gold Camp and its capacity for major discoveries. Nighthawk's continued exploration success on its satellite targets supports the conviction that Colomac is not the only multi-million-ounce deposit in the camp. The many prominent regional targets provide a remarkable opportunity for growth and collectively strengthen the Company's 100% controlled regional play centered on Colomac. Many of these targets are at an early exploration stage and require additional work to unlock their ultimate potential, which the Company intends to follow up on in future regional programs.

Treasure Island

Treasure Island lies 11 km north of Colomac along the eastern end of the Treasure Island – Laurie Lake Mineralized Corridor, an underexplored 7 km long domain host to several high-priority gold showings (Figure 2). Mineralization consists of several en-echelon stacked zones spanning a regional east-west volcanic rock/sedimentary rock contact. Drilling to-date has outlined a 200-metre-wide and 750-metre-long assemblage of strongly altered rock that spans the southern shoreline of the island hosting the Main Zone and East Zone deposits.

In 2019 Nighthawk successfully completed its third drill campaign at Treasure Island to follow up on targets developed in both of its prior programs, where drilling confirmed and expanded on previous Nighthawk field reconnaissance programs (see press release dated February 4, 2020). Drilling explored the western and depth extensions of the Main Zone and the 300 metres of untested ground that lies between the two zones, resulting in the extension of the Main Zone up to 50 metres further west and infilling mineralization along strike between the zones (Table 1). All targets remain open along strike and to depth.

Given its extensive broad mineralized envelope with internal higher-grade domains, and with over 75 percent of the 7 km long mineralized corridor still unexplored, it represents exceptional untapped discovery potential. Treasure Island is considered a key satellite prospect proximal to Colomac and remains a focus of future exploration.

Table 1. Treasure Island 2019 Drilling Selected Results

Drill Hole

Assay Results

T19-01

6.25 m at 12.08 gpt Au

Including

2.50 m at 25.61 gpt Au

T19-01B

6.50 m at 10.20 gpt Au

Including

3.75 m at 16.38 gpt Au

T19-11

12.70 m at 8.51 gpt Au

Including

7.30 m at 14.06 gpt Au

T19-12

20.70 m at 2.57 gpt Au

including

8.20 m at 5.64 gpt Au

Andy Lake

Andy Lake is located 20 km south of Colomac within the Gamey Lake Volcanic Panel; a NE-SW trending volcanic rock assemblage bordered by metasedimentary rocks to the east and west and intruded by the Andy Lake Granodiorite and associated granitoid dykes (Figure 1). In 2018 a 1:20,000 scale mapping program covering much of the panel led to the discovery of several new surface showings of high-grade gold mineralization up to 42.10 gpt Au hosted in multiple parallel north-trending shear zones within the granodiorite. Andy Lake is interpreted to be an orogenic style of gold mineralisation where gold-bearing quartz veins are hosted in the Andy Lake Granodiorite. The area is also anomalous in Silver (Ag), Bismuth (Bi), Molybdenum (Mo), Lead (Pb), and Copper (Cu).

The five sites that returned high-grade samples in the 2018 campaign were the focus of detailed follow-up exploration work in 2019 (Figure 3). Mechanical outcrop stripping and power washing was completed at four of the sites (A, B, C and E) over a 500 m N-S and 250 m E-W area where removal of all overburden material allowed for more expansive and detailed mapping (1:50 scale) and channel sampling. Local bedrock consists of strongly altered intrusive and volcanic rocks hosting a series of parallel N-S trending, steeply east-dipping, shears with associated mineralized quartz veins. Forty-three channels that ranged in length from 0.5 meters to 9.0 meters were cut into outcrops at the four sites totaling 147.75 metres. Of the 316 channel samples collected, 61 samples returned gold values greater than or equal to 0.54 gpt Au with the highest being 42.80 gpt Au. Sampling at all sites returned anomalous gold values suggesting that the region between and peripheral to the four sites is highly prospective (Figure 3).

The four mineralized shears described in the stripped areas, as well as several additional targets yet to be evaluated, form an echelon left-stepping fault array that developed in the host volcanic and intrusive rocks. Collectively, the shears define a highly prospective broader structural corridor, the Andy Lake mineralized corridor, that is approximately 500 meters N-S by 250 meters E-W and open in all directions.

The Andy Lake mineralized corridor is one of the Company's most prospective and undrilled gold targets within the Indin Lake Gold Camp. The presence of high-grade gold mineralization coupled with nested shear zones having an extensive areal footprint, defines another significant gold corridor within the Indin Lake Greenstone Belt that warrants further exploration.

Site A

Of the four areas, Site A returned the best gold values to-date (Figure 3). Ten channels were laid out over an outcrop area of 50 meters N-S by 20 meters E-W and spaced at 4-meter to 7-meter intervals with individual lengths ranging from 0.5 meters to 7.0 meters. All channels returned anomalous gold samples ranging from detection limit to 42.80 gpt Au (Table 2). Mineralization is open in all directions and to depth.

Table 2. Andy Lake Site A – 2019 select channel and grab sample results

Channel

Sample

Easting

Northing

Au (gpt)

Grab

A0563377

593044

7122854

42.80

A1

A0563685

593042

7122886

1.33

A2

A0563696

593044

7122882

1.18

A3b

A0563644

593043

7122866

1.69

A5

A0563630

593045

7122853

1.77

A5

A0563633

593045

7122853

1.58

A6b

A0563670

593046

7122882

1.40

A6b

A0563669

593046

7122882

1.20

A6c

A0563673

593047

7122875

2.78

A6c

A0563672

593047

7122875

1.37

A7

A0563647

593048

7122872

2.80

A7

A0563651

593048

7122872

2.35

A7

A0563654

593050

7122872

2.27

A7

A0563650

593048

7122872

1.74

A7

A0563652

593048

7122872

1.13

A8

A0563634

593042

7122862

2.45

A8

A0563636

593042

7122862

1.51

A9a

A0563619

593034

7122852

1.17

A9b

A0563622

593039

7122852

2.68

Sites B, C, E

Seven channels ranging in length from 0.5 meters to 7.0 meters, and spaced less than 2.0 meters apart, were cut over 100 m2 at Site B. All channels returned anomalous samples but nothing above 0.25 gpt Au was noted. Eight channels were completed at Site C ranging in length from 0.5 meters to 8.0 meters to sample an outcrop area of 360 m2. Channels were cut into all lithologies to sample across shear veins and tension gashes. A total of 58 channel samples were collected that returned assays up to 2.74 gpt Au. At site E, 18 channels ranging in length from 0.5 meters to 7.0 meters were completed and 108 channel samples were collected returning assays up to 5.06 gpt Au (Table 3).

Table 3. Andy Lake Sites C and E – 2019 select channel sample results

Channel

Sample

Easting

Northing

Au (gpt)

C1

A0563763

592948

7122544

0.47

C1

A0563758

592952

7122549

0.38

C5

A0563781

592949

7122536

1.18

C7

A0563791

592964

7122532

2.74

C7

A0563790

592964

7122532

1.04

C7

A0563789

592964

7122532

0.60

C7

A0563796

592964

7122532

0.42

E5a

A0563539

592983

7122707

0.71

E14

A0563559

592971

7122689

5.06

E16

A0563568

592949

7122688

1.52

E16

A0563569

592949

7122688

0.42

E17

A0563572

592950

7122686

2.37

E18

A0563573

592948

7122684

1.36

Barker-Vidie – High-grade gold showing

Barker-Vidie is located 27 km south-southwest of Colomac within a N-S trending volcanic rock assemblage. The showing is underlain by strongly carbonate altered intermediate to mafic volcanic rocks (Figure 1 & 4). In 2019 prospecting at Barker-Vidie was directed to follow-up on a 23.60 gpt Au grab sample collected in 2018. A total of 53 grab samples were taken along the E-W and N-S trending portion of the Indin Lake shoreline returning assays up 13.65 gpt Au (Table 4). Work in 2019 has increased the strike length of the high-grade showing to 300-meters highlighting the untapped potential of this showing.

Table 4. Barker-Vidie – 2019 select grab sample results

Sample

Easting

Northing

Au (gpt)

A0563343

586278

7115895

13.65

A0562724

586369

7115684

12.10

A0562726

586238

7115952

5.36

Zone 24 surface gold showing – Part of the Colomac Gold Project ("Colomac")

The Zone 24 and nearby Zone 27 deposits are near-surface gold deposits located 4.5 km northeast of Colomac (Figure 5) that are included in Nighthawk's 2018 Colomac Gold Project mineral resource estimate (see press release dated June 13, 2018). Although never drilled by the Company, surface work at Zone 24 in 2019 focused on developing a better understanding of the controls on mineralization which is needed to help direct future drilling to expand on this promising deposit.

The two deposits lie along a north-trending high-strain zone that follows a felsic to intermediate volcanic rock and metasedimentary rock contact with a gabbroic intrusion sandwiched between them (Figure 5). Zone 24 outcrops exhibit intense rusty brown iron oxide surface weathering with milky white to smoky grey quartz flooding and semi-massive sulfide patches common within the southern portion of the showing. Fieldwork in 2019 extended the area of interest towards the north highlighted by an 8.38 gpt Au grab sample. Zone 24 and Zone 27 have received limited exploration attention yet remain a high priority exploration target for resource expansion as does the area between the two deposits and along strike.

Fishhook- New high-grade samples

Fishhook is located 40 km south of Colomac and is the southern most project within Nighthawk's Indin Lake Gold Property (Figure 1 & 6). Gold showings are hosted in a series of complex folded amphibolitic oxide-silicate iron formations that span several kilometres. Detailed outcrop sampling in 2018 returned several high-grade results up to 174.50 gpt Au (Figure 6). In 2019 field activities were limited to expanding on some of these results, including sampling areas lateral to the 2018 high-grade sample, which returned grab samples up to 6.25 gpt Au over an 86-meter strike length (Table 5).

Fishhook bears a strong resemblance to the Company's Damoti Lake Gold Deposit, a high-grade gold deposit located northeast of Fishhook. Fishhook has received little exploration attention from Nighthawk to-date, however, its high-grade nature, structural style, host lithology and extensive mineralized footprint are comparable to the many iron formation hosted gold deposits in other Archean greenstone belts, thus solidifying its position as one of the Company's top prospects.

Table 5. Fishhook – 2019 select grab sample results

Sample

Easting

Northing

Au (gpt)

A0562715

587122

7104955

6.25

A0562100

587122

7104959

1.83

A0562309

587119

7105009

1.63

A0562311

587119

7105009

1.21

A0562712

587122

7104955

0.85

A0562315

587117

7105041

0.36

A0562310

587119

7105009

0.36

Regional Mapping: Albatross gold trend, Nice Lake sill, Santa Zone and Laurie Lake showings

The Albatross gold trend lies 15 km southwest of the Colomac deposit (Figure 1), within a couple of hundred metres from a decommissioned all-season haulage road that links the Cass and Kim gold deposits with the past-producing Colomac mine. Previous samples of up to 10.30 gpt Au were collected from gold showings associated with brittle-ductile high strain zones that separate units of meta-volcanic and intrusive rocks from meta-sedimentary rocks. Intrusion-hosted and volcanic-hosted showings are recognized in association with the brittle-ductile high strain zones.

The 2019 field program helped advance the Albatross gold trend as several anomalous grab samples were collected that assayed up to 3.34 gpt Au. Nighthawk is encouraged with the results to-date and believes that the area has the potential to host similar opportunities as the nearby Cass gold deposit.

Grid sampling was conducted along the Nice Lake sill (Figure 1) located 2 km southeast of Colomac. The sill was discovered in 2016 and has since been the focus of expanded field activities, highlighted by 2018 grab samples that returned 41.90 gpt Au, 38.90 gpt Au, and 19.05 gpt Au. Nice Lake and the recently discovered Santa Zone prospect located along strike and north of Nice Lake, are underlain by an intercalated sequence of massive and pillowed basalt-andesite flows, concordant gabbroic sills, felsic flows, pyroclastic and epiclastic rocks. Two different types of syn-volcanic sills are present, high-level feldspar+quartz porphyries and those of gabbro-diorite composition. Sub vertical north-trending shears parallel the volcanic stratigraphy. The structural setting of the Nice Lake corridor with north-trending strain zones and brittle syn-volcanic intrusions is comparable to the structural setting of the Colomac Main Sill. Consequently, the Nice Lake corridor, which extends 4-5 kilometres to the south, remains a key exploration target for the Company.

The Laurie Lake showings are located 8.5 km northwest of Colomac along the western extent of the Treasure Island-Laurie Lake Mineralized Corridor (Figure 1). Regional geology consists of alternating units of mafic meta-volcanic rocks and turbiditic meta-sediments. In 2019, detailed geological mapping covered a 2.34 km area where high-grade gold grab samples were taken from quartz veins in 2018. This latest program was successful in identifying several new priority targets for future investigations.

Two historical gold showings south of Colomac, MAR A-Zone and LOM 2633-6, were also investigated in 2019 (Figure 1). Work in both areas has validated historical reports of mineralization as grab samples up to 1.16 gpt Au were collected from outcrop exposures proximal to the showings and have identified new targets worthy of further work.

Figure 1. Indin Lake Gold Property – 2019 Regional Bedrock Sampling

Figure 2. Treasure Island – 2019 Drillhole Locations

Figure 3. 2019 Andy Lake Channel Samples and Mapped Sites (red polygons).

Figure 4. Barker-Vidie Surface Sample Location Map.

Figure 5. Zone 24 Surface Sample Location Map.

Figure 6. Fishhook Surface Sample Location Map.

Technical Information

Nighthawk has implemented a quality-control program to comply with best practices in the sampling and analysis of drill core. Drill core samples were transported in security-sealed bags for analyses at ALS Global Assay Laboratory in Vancouver, BC ("ALS Global"). ALS Global is an ISO/IEC 17025 accredited laboratory. Pulp and metallics assaying for gold was conducted on the entire pulverized sample.

As part of its QA/QC program, Nighthawk inserts external gold standards (low to high-grade) and blanks every 20 samples in addition to the standards, blanks, and pulp duplicates inserted by ALS Global.

About Nighthawk

Nighthawk is a Canadian-based gold exploration company with 100% ownership of a district-scale land position within the Indin Lake Greenstone Belt, located approximately 200 km north of Yellowknife, Northwest Territories, Canada. Nighthawk is focused on advancing the Colomac Gold Project with a current inferred resource of 2.6 million ounces of gold (50.3 million tonnes at an average grade of 1.62 grams per tonne gold), as well as advancing its other regional gold deposits and showings within this largely underexplored Archean gold camp.

The Company has an experienced and dedicated team and is well funded to complete its goals and objectives over the next 12 months.

Qualified Person

Dr. Michael J. Byron, Ph.D., P.Geo., President & Chief Executive Officer of Nighthawk, who is the "Qualified Person" as defined by NI 43-101 for this project, has reviewed and approved of the technical disclosure contained in this news release. Please refer to NI 43-101 technical report "Technical Report and mineral resource estimate update on the Colomac Property of the Indin Lake Project", dated June 13, 2018, as filed under the company's profile on www.sedar.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

NIGHTHAWK GOLD CORP.

Tel: 1-647-794-4313

Email: info@nighthawkgold.com

Website: www.nighthawkgold.com

Dr. Michael Byron
President & CEO
Tel: 1-647-794-4359

Michael Leskovec
CFO
Tel: 1-647-794-4360

Suzette N Ramcharan
VP, Corporate Development
Tel: 1-647-794-4362

Neither the Toronto Stock Exchange has neither reviewed nor accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Information

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, information with respect to the Company's continued exploration programs (including size and budget) and the ability to advance targets; the ability to grow ounces at Colomac, the ability to raise the necessary capital on acceptable terms in order to conduct exploration programs including mapping, prospecting and drilling activities and identify new targets in future years, as well as any intention to expand these programs in the future. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved".

Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is based on a number of assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Nighthawk to be materially different from those expressed or implied by such forward-looking information, including risks associated with the exploration, development and mining such as economic factors as they effect exploration, future commodity prices, changes in foreign exchange and interest rates, actual results of current exploration activities, government regulation, political or economic developments, environmental risks, permitting timelines, capital expenditures, operating or technical difficulties in connection with development activities, employee relations, the speculative nature of gold exploration and development, including the risks of diminishing quantities of grades of reserves, contests over title to properties, and changes in project parameters as plans continue to be refined as well as those risk factors discussed in Nighthawk's annual information form for the year ended December 31, 2017, available on www.sedar.com. Although Nighthawk has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Nighthawk does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

SOURCE: Nighthawk Gold Corp

ReleaseID: 594870

MONTREAL, QC / ACCESSWIRE / June 23, 2020 / Quebec Precious Metals Corporation ("QPM" or the "Company") (TSXV:CJC)(OTCQB:CJCFF)(FSE:YXEP) is pleased to announce that it is has resumed exploration activities on its 100%-owned Sakami project in the Eeyou Istchee James Bay territory of Quebec. The activities include a 7,000 m diamond drilling program in the area of the La Pointe Extension discovery using one drill rig. Drilling can be performed year-round (see press releases of January 14, April 21 and June 18, 2020).

The objective is to expand the La Pointe Extension discovery, which consists of several significant drill hole intersections, including 1.15 g/t Au over 80.1 metres. The recent drilling at the La Pointe Extension discovery indicates a gold mineralized system and significant exploration potential 2 km to the southwest of the La Pointe deposit. The drilling targets are defined by spatially correlated induced polarization ("IP") and gold-arsenic soil geochemical anomalies as well as gold-bearing surface showings along a well-defined mineralized trend.

The activities during June comprise:

an IP survey to expand the known anomalies to the southwest;
capture of down-hole wall imaging data in selected drill holes to assist with the geological interpretation; and
a bathymetry survey near the shoreline of the La Pointe deposit area.

QPM has implemented a rigorous protocol to ensure the protection of all stakeholders in the region and in accordance with the INSPQ and CNESST guidelines during the COVID-19 pandemic. The Company's protocol has been communicated to and reviewed by the Cree Nation Government. QPM recognizes the excellent cooperation on the part of the Cree authorities to help with exploration programs during this challenging period. The Company concluded its winter program exploration programs on March 25, 2020, to respect the Government of Quebec's decree in response to the COVID-19 pandemic.

Qualified Persons

Normand Champigny, Eng., Chief Executive Officer of the Company, and Jean-Sébastien Lavallée (OGQ #773), geologist, Vice-President Exploration, director and shareholder of the Company, both Qualified Persons under NI 43- 101 on standards of disclosure for mineral projects, have prepared and approved the technical content of this release.

About Quebec Precious Metals Corporation

QPM is a gold explorer with a large land position in the highly-prospective Eeyou Istchee James Bay territory, Quebec, near Newmont Corporation's Éléonore gold mine. QPM's flagship project is the Sakami project with significant grades and well-defined drill-ready targets. QPM's goal is to find the next gold mine in this territory.

For more information please contact:

Jean-François Meilleur
President
Tel.: 514 951-2730
jfmeilleur@qpmcorp.ca

Normand Champigny
Chief Executive Officer
Tel.: 514 979-4746
nchampigny@qpmcorp.ca

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Quebec Precious Metals Corporation

ReleaseID: 594797

MARKHAM, ONTARIO / ACCESSWIRE / June 23, 2020 / iFabric Corp. ("iFabric") (TSX:IFA), today provides details of its test results about the efficacy of PROTX2 treated fabrics for inactivating an additional Human Coronavirus (229E).

IFabric advises that efficacy testing of PROTX2 treated fabric against this additional Human Coronavirus, type 229E, was carried out by an internationally recognized, independent laboratory in the United States, to establish its ability to inactivate the virus at time points of 10 minutes and 1 hour. The Laboratory reported that the treated fabrics demonstrated a greater than 99% reduction in active viral loads on the tested fabrics at each of the two time points. This supplements prior testing to establish the efficacy of PROTX2 treated fabrics against the SARS-CoV-2 Human Coronavirus, which causes the COVID-19 disease.

"Continued confirmation of PROTX2's broad spectrum antiviral efficacy is an important milestone. This additional data forms part of our ongoing strategy to provide textiles with greater levels of protection against viruses and bacteria." stated Giancarlo Beevis, President and CEO of iFabric subsidiary Intelligent Fabric Technologies (North America) Inc. ("IFTNA"). "This new data will aid ITFNA in its mission to create the new standard in protective textiles and help in the struggle to reduce the risk and speed of contamination and transmission around the world", concluded Mr. Beevis.

About iFabric Corp.

Headquartered in Markham, Ontario, iFabric Corp www.ifabriccorp.com is listed on the TSX and currently has 26.4 million shares issued and outstanding. Through its wholly-owned subsidiaries, Intelligent Fabric Technologies (North America) Inc. ("IFTNA") and Coconut Grove Pads Inc. ("Coconut Grove"), the Company offers a variety of products and services in both of its strategic divisions:

IFTNA is focused on performance apparel as well as proprietary chemical formulations that render fabrics, foams, plastics and numerous other surfaces intelligent, thereby improving the safety and well-being of consumers.

Coconut Grove, operating as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of ladies intimate apparel products and accessories.

Forward looking information

Forward-looking statements provide an opinion as to the effect of certain events and trends on the business. Certain statements contained in this news release constitute forward looking statements. The use of any words such as "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Forward-looking information includes, but is not limited to, statements with respect to the efficacy testing of the Company's products and results and timing thereof as well as the review of the approvals of the Company's products. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the adequacy, timing, and results of testing of our products, the regulatory approval process, competition, market acceptance of the Company's products, the strength of intellectual property, the success of research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to-time in our filings with the Canadian securities regulators.

The Company cannot provide any assurance that forward-looking statements will materialize. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or any other reason except as required by applicable securities laws.

The forward-looking statements contained in this press release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

FOR FURTHER INFORMATION, please contact:

Hilton Price, CFO
Tel: 647.465.6161
Email: hilton.price@rogers.com

Gary Perkins – Investor Relations
Tel: 416.882.0020
Email: garyperkins@rogers.com

Jean-François Dubé (Québec) – Investor Relations
Tel: 514.233.9551
Email: jfdube@mac.com

Website: http://www.ifabriccorp.com/

Neither the TSX nor its Regulations Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE: iFabric Corp

ReleaseID: 594816

NEW YORK, NY / ACCESSWIRE / June 23, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Groupon, Inc. (NASDAQ:GRPN)
Class Period: November 4, 2019 – February 18, 2020
Lead Plaintiff Deadline: June 29, 2020

Groupon, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing fewer customer engagements in its Goods category; (2) Groupon relied on its Goods category to drive its sales, especially during the holiday season; (3) as a result of the foregoing, the Company was likely to experience reduced sales; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in GRPN: http://www.kleinstocklaw.com/pslra-1/groupon-inc-loss-submission-form?id=7492&from=1

Grand Canyon Education, Inc. (NASDAQ:LOPE)
Class Period: January 5, 2018 – January 27, 2020
Lead Plaintiff Deadline: July 13, 2020

According to a filed complaint, statements made by Defendants were false and/or misleading because, following Grand Canyon's spin-off of its educational assets as Grand Canyon University ("GCU"): (i) GCU would not be a proper non-profit organization as it would remain under the control of Grand Canyon, and (ii) Grand Canyon would not be a third-party service provider to GCU but rather would continue to effectively operate the entity, and (iii) Grand Canyon employees served as executives of GCU and (iv) GCU functioned as an off-balance-sheet entity to which Grand Canyon would be able to funnel expenses and costs in exchange for a disproportionate amount of revenue, thereby inflating Grand Canyon’s financial results.

Learn about your recoverable losses in LOPE: http://www.kleinstocklaw.com/pslra-1/grand-canyon-education-inc-loss-submission-form?id=7492&from=1

Forescout Technologies, Inc. (NASDAQ:FSCT)
Class Period: February 6, 2020 – May 15, 2020
Lead Plaintiff Deadline: August 10, 2020

During the class period, Forescout Technologies, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Forescout was experiencing a significant and disproportionate decline in its financial performance; (2) the foregoing was reasonably likely to have a material negative impact on Forescout’s planned acquisition by Advent International Corp.; and (3) as a result of the foregoing, defendants’ statements about its business and operations were materially false and misleading at all relevant times.

Learn about your recoverable losses in FSCT: http://www.kleinstocklaw.com/pslra-1/forescout-technologies-inc-loss-submission-form-2?id=7492&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 594900

NEW YORK, NY / ACCESSWIRE / June 23, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

PRA Shareholders Click Here: https://www.zlk.com/pslra-1/proassurance-corporation-loss-form?prid=7491&wire=1
WFC Shareholders Click Here: https://www.zlk.com/pslra-1/wells-fargo-company-loss-submission-form?prid=7491&wire=1
ENPH Shareholders Click Here: https://www.zlk.com/pslra-1/enphase-energy-inc-loss-submission-form?prid=7491&wire=1

* ADDITIONAL INFORMATION BELOW *

ProAssurance Corporation (NYSE:PRA)

PRA Lawsuit on behalf of: investors who purchased April 26, 2019 – May 7, 2020
Lead Plaintiff Deadline : August 17, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/proassurance-corporation-loss-form?prid=7491&wire=1

According to the filed complaint, during the class period, ProAssurance Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) ProAssurance lacked adequate underwriting process and risk management controls necessary to set appropriate loss reserves in its Specialty P&C segment; (ii) ProAssurance failed to properly assess a large national healthcare account that experienced losses far exceeding the assumptions made when the account was underwritten; and (iii) as a result, ProAssurance was subject to materially heightened risk of financial loss and reserve charges.

Wells Fargo & Company (NYSE:WFC)

WFC Lawsuit on behalf of: investors who purchased April 5, 2020 – May 5, 2020
Lead Plaintiff Deadline : August 3, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/wells-fargo-company-loss-submission-form?prid=7491&wire=1

According to the filed complaint, during the class period, Wells Fargo & Company made materially false and/or misleading statements and/or failed to disclose that: (i) Wells Fargo planned to, and did, improperly allocate government-backed loans under the Paycheck Protection Program ("PPP"), and/or had inadequate controls in place to prevent such misallocation; (ii) the foregoing foreseeably increased the Company's litigation risk with respect to PPP allocation, as well as increased regulatory scrutiny and/or potential enforcement actions; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Enphase Energy, Inc. (NASDAQ:ENPH)

ENPH Lawsuit on behalf of: investors who purchased February 26, 2019 – June 17, 2020
Lead Plaintiff Deadline : August 17, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/enphase-energy-inc-loss-submission-form?prid=7491&wire=1

According to the filed complaint, during the class period, Enphase Energy, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 594899

SHELTON, CT / ACCESSWIRE / June 23, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its third quarter of financial year 2020 with the Securities and Exchange Commission. The Company had requested a COVID-19-related extension to file the quarterly report. This press release should be read in conjunction with the Form 10-Q filed on June 22, 2020. The submission can be downloaded from the SEC website at: https://www.sec.gov/Archives/edgar/data/1379006/000110465920075651/0001104659-20-075651-index.htm.

The Company reported that it had approximately $6.44 Million (M) of current assets (cash, cash equivalents, and prepaid expenses), and current cash liabilities of approximately $1.14M excluding a recent mortgage (described below), as of March 31, 2020, the end of the reporting period. The net cash used in operating activities during the nine months period was approximately $5.11M. The Company's expenditures were in line with budget estimates. Shareholder equity stood at approximately $14.31M for the quarter (unaudited figures), primarily due to the asset value of its cGMP-capable manufacturing facility, R&D labs, and equipment, that it owns fully except for a $2 Million secured debt provision, and the net proceeds of the equity raise completed on or about January 22, 2020. The Company had no revenues. The Company has no long-term debt.

Previously, the Company drew down $1.1M from a $2M non-convertible loan commitment secured by a mortgage on the Company's facility provided by the Company's founder and President, Anil R. Diwan, PhD., in December 2019. The mortgage is payable in full on March 31, 2021, with no payments due until then. Interest is payable only on amounts drawn by the Company.

The Company has previously reported that it has raised approximately $8.625M in gross proceeds in an underwritten public offering, pursuant to an effective Form S-1 registration statement, comprising the sale of 2.5 million shares plus 375,000 shares of an underwriters over-allotment option at a price of $3 per share, with no warrants issued in the transaction, that closed on or about January 22, 2020. Aegis Capital Corp. acted as sole bookrunner for the offering. The net proceeds to the Company after underwriter's commission and agreed upon customary fees and expenses were approximately $7.78 million, before deducting the Company's legal and accounting expenses related to the Offering.

The Company has previously reported on May 22, 2020, that it had raised approximately $10.22M in gross proceeds in a registered direct offering of 1,400,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share at the purchase price of $7.30 per share. No warrants were issued in this offering. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc. acted as placement agents in connection with this Offering. The net proceeds to the Company from this offering were approximately $9.3 million after placement agent fees and other estimated offering expenses payable by the Company.

With these cash inflows, the Company believes its balance sheet is now strong and the Company has sufficient funding for its planned expenditures for the ensuing year, based on estimated budgets including costs of certain clinical trials.

The Company has previously reported that it is working on developing a therapeutic drug for the treatment of the novel coronavirus 2019-nCoV, a/k/a COVID-19. In 2014, the Company had engaged in drug discovery efforts against MERS coronavirus. The Company had reported in a press release on January 20, 2020, that it has already found broad-spectrum virus-binding ligands that are expected to attack the virus at the same points that the virus uses to bind to its cognate cellular receptor, namely ACE-2 (angiotensin converting enzyme type 2), using molecular modeling based on known SARS-CoV and ACE2 interactions. COVID-19 shares significant similarity with, and uses the same cellular receptor as, SARS-CoV.

On May 12, 2020, the Company announced that it has developed drug candidates against coronaviruses that have demonstrated very high anti-viral effectiveness in cell culture studies against multiple coronaviruses. Two of the tested nanoviricides drug candidates were highly effective in cell culture assays against multiple coronaviruses that infect humans. The Company has tested its drug candidates for anti-viral effectiveness against two distinctly different, unrelated coronaviruses that cause human disease, namely HCoV-NL63, and HCoV-229E. The assays evaluated the reduction caused by the drug candidate in cell death upon viral infection, formally known as cytopathic effects (CPE) assays. In particular, some of the tested nanoviricide drug candidates were several-times more effective than favipravir (aka T-705), against the tested viruses. Favirpravir is a broad-spectrum nucleoside-like analog drug that is in clinical testing against SARS-CoV-2, originally developed by Fujifilm.

On May 19, 2020, the Company announced that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases. The Company is developing an animal model for coronavirus infection using hCoV-NL63 as a surrogate for SARS-CoV-2, the virus that causes COVID-19 disease. HCoV-NL63 is a circulating human coronavirus that causes a disease that is similar to SARS-CoV-2, but much milder. Both viruses utilize the same cell receptor, namely ACE2, to gain entry into the cell. Because it causes a mild disease, hCoV-NL63 can be used in BSL2 environments, and the Company believes it is a useful surrogate for development of therapeutics against SARS-CoV-2 infection.

In this lethal direct-lung-infection model, animals in all groups developed lung disease that later led to multi-organ failures, a clinical pathology resembling that of the SARS-CoV-2. Reduction in loss of body weight at day 7 was used as the primary indicator of drug effectiveness. Rats were infected directly into lungs with lethal amounts of HCoV-NL63 virus particles and then different groups were treated separately with five different nanoviricides drug candidates, remdesivir as a positive control, and the vehicle as a negative control. The treatment was intravenous by tail-vein injection once daily for five days, except it was twice daily in the case of remdesivir.

Animals treated with five different nanoviricides showed significantly reduced body weight loss. The body weight loss was only 3.9% for the best nanoviricide candidate, ranging to 11.2% for the potentially least effective one, as compared to 20% in the vehicle-treated control group, in female animals (n=5 in each group). Male animals treated with the same nanoviricides also showed significantly reduced body weight loss. The body weight loss in male animals was 8.0% for the best nanoviricide candidate and ranged up to 10.9% for the potentially least effective one, as compared to 25% in the vehicle-treated control group (n=5 in each group). In comparison, remdesivir treatment led to a body weight loss of 15.2% in females and 18.6% in males in this study (see below). Smaller numbers mean less loss in body weight compared to starting body weight in the group, and indicate greater drug effectiveness.

The strong effectiveness of nanoviricide drug candidates in this model is consistent with the effectiveness observed in cell culture studies against infection of both hCoV-NL63, which was used in this study, and hCoV-229E, another circulating coronavirus that uses a distinctly different receptor, namely APN.

Thus this animal study corroborated the cell-culture effectiveness reported by the Company and provides confidence to the Company that these nanoviricides drug candidates may be expected to result in a clinical candidate to be pursued in human clinical trials.

The Company believes the fact that these nanoviricides anti-coronavirus drug candidates are highly effective against two distinctly different coronaviruses that use different cellular receptors is very significant. Specifically, it provides a rational basis to scientists indicating that even if the SARS-CoV-2 coronavirus mutates, the nanoviricides can be expected to continue to remain effective. Antibodies and vaccines in general cannot be expected to remain effective if the virus undergoes genomic changes.

Importantly, nanoviricides are designed to act by a novel mechanism of action, trapping the virus particle like the "Venus-fly-trap" flower does for insects. Antibodies, in contrast, only label the virus for other components of the immune system to take care of. It is well known that the immune system is not functioning properly at least in severe COVID-19 patients.

Prior to filing for human clinical trials, the Company plans on conducting studies to further determine the effectiveness against SARS-CoV-2, perform drug development studies for safety/toxicology, and request a pre-IND Meeting with the US FDA for regulatory guidance.

The Company is developing a therapy or drug to combat the SARS-CoV-2 virus itself, for the treatment of infected patients, and not a drug that is designed for reducing clinical symptoms alone. The drug we are developing is not a vaccine, and does not have to be given to everyone, but will need to be given only to patients, if we can develop it successfully.

The Company has the capacity to produce several thousand doses of the potential drug at its cGMP-capable multi-purpose manufacturing facility in Shelton, CT, depending upon the treatment course. If our COVID-19 drug program produces positive results, then the Company anticipates obtaining assistance from US government and international agencies for further testing and potential exploratory clinical use to combat the epidemic. The Company does not at present have any active collaborations with US or international agencies for this purpose. The outbreak was declared a global emergency by the WHO on the same date as our announcement that we were working on therapeutics development against SARS-CoV-2, January 30, 2020, and has since turned into a global pandemic with devastating consequences around the world.

Subsequent to the reporting period, on June 8, 2020, the Company announced that it executed a Memorandum of Understanding ("MoU") with TheraCour Pharma, Inc. ("TheraCour") for a license for the research and development of anti-viral treatments for coronavirus derived human infections. The MoU also provides a limited license to the Company for the entire application of human coronavirus infections, while the full license is to be perfected by August 31, 2020. The Company is in the process of appointing a third party consulting firm for independent evaluation of this market space. Dr. Anil Diwan is recused from these discussions due to a conflict of interest.

Several coronaviruses have become endemic human pathogens, such as hCoV- 229E, NL63, OC43, and HKU1. These continually circulate in the human population and cause respiratory infections in adults and children world-wide. In contrast, SARS-CoV has caused only one well-known epidemic, with a mortality rate of about 9%, and MERS-CoV has caused repeated outbreaks, with mortality rates approaching 35%, but with limited number of cases. A broad-spectrum anti-coronavirus drug, such as a broad-spectrum nanoviricide that the Company is currently developing, could be potentially useful for treating most if not all of the different coronavirus infections that occur every year, and not just for coronavirus epidemics.

The Company has experience developing broad-spectrum cellular receptor mimetics as virus-binding ligands for creating nanoviricide drugs. The Company has demonstrated this capability notably in its HerpeCide™ program, wherein nanoviricides based on the same antiviral ligand were found to be effective against at least three different kinds of herpesviruses, namely herpes simplex-1 (HSV-1), herpes simplex-2 (HSV-2), and, surprisingly, the non-simplex varicella zoster virus (VZV).

The Company continues to advance its first drug candidate, namely NV-HHV-101 skin cream, for the treatment of shingles rash as its first indication, towards human clinical trials.

The Company is now in the process of writing and completing its first IND ("Investigational New Drug") application to the US FDA, which includes protocols for human clinical studies, with the help of its several regulatory consultants. This application covers the indication of the Company's drug, namely, NV-HHV-101 skin cream for the treatment of shingles rash, caused by VZV (varicella-zoster virus). The IND-enabling and required pre-clinical studies have been completed, and reports of almost all of the analyses of the samples resulting from these studies are being circulated between parties involved for completion. The Company is in the process of identifying and selecting appropriate partners and collaborators for the intended Phase1/2a human clinical studies for this drug candidate. The Company cannot project an exact date for filing an IND because of its dependence on a number of external collaborators and consultants, and the effects of recent COVID-19 restrictions.

The Company has undertaken cGMP manufacture of the drug product, namely, NV-HHV-101 skin cream, indicated for the topical treatment of shingles rash, for supplying anticipated Phase I human clinical trials at its own facility. The Company has industry-leading internal expertise in the cGMP manufacture of complex nanomedicines drugs, right from simple starting materials to formulated drug products.

In a human skin patch organ culture model ex vivo, the Company has previously demonstrated the effectiveness and safety of topical NV-HHV-101 against VZV, the cause of shingles and chickenpox. These studies were conducted by Professor Jennifer Moffat at the Upstate Medical Center, SUNY Syracuse, NY. Professor Moffat has developed this model for pre-clinical evaluation of therapeutics against VZV, and is a well-known expert in the field.

It is anticipated that the high effectiveness of our clinical drug candidate observed in this human skin model should be predictive of effectiveness in human clinical trials for topical dermal treatment of shingles.

NanoViricides is pioneering a unique platform for developing anti-viral drugs based on the "bind-encapsulate-destroy" principles. Viruses would not be able to escape a properly designed nanoviricide® drug by mutations because in doing so they would lose the ability to bind their cognate cellular receptor(s) and thus fail to infect productively, becoming incompetent.

About NanoViricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

ReleaseID: 594895

VANCOUVER, BC / ACCESSWIRE / June 23, 2020 / Vancouver, British Columbia- Gold Springs Resource Corp. (TSX:GRC)(OTCQB:GRCAF) (the "Company" or "GRC"), is pleased to announce that yesterday, the Company has commenced a ground-based geophysical survey, known as CSAMT, on the Utah side of the Gold Springs project. The survey will be conducted by Zonge International, a well-known geophysical services company based in Reno, Nevada USA.

The CSAMT survey will fill gaps left by a previous CSAMT survey done at Gold Springs in 2004. These gap zones are located in the Jumbo trend and include the Central Jumbo target, which is the area between the North and South Jumbo resource blocks, the northern-extension of the North Jumbo resource, the northern extension of the Juniper target, as well as the western extension of the South Jumbo Resource block, which also includes the Fitch target.

The CSAMT survey is an important component of GRC's 2020 exploration program as it will attempt to better delineate mineralized zones which are closely associated with resistivity anomalies. The surveys will help to further define some of the priority targets and aid in future drill planning. Geophysical data for these gap zones is covered by the existing ZTEM (Z-Tipper Electromagnetic System) airborne geophysics survey done at Gold Springs, however, the ground geophysical data provides greater details and helps identify mineralized structures within the trends thus aiding in drill hole targeting.

Matias Herrero, President and CEO of GRC commented "Geophysics plays a significant role in the successful targeting of gold mineralization at Gold Springs. Our existing four resources at Gold Springs are all associated with high resistivity geophysical responses. What is exciting about the future of the project is that all of the 24 additional targets at Gold Springs are closely associated with resistivity highs seen from the ZTEM and CSAMT surveys". Mr. Herrero further commented "We are looking forward to the collection of the CSAMT data which will allow us to better understand the structural corridors and faulting systems within the Jumbo trend and to refine the existing drill target areas as well as generating new surface and buried targets".

CSAMT raw data will be processed and interpreted, with results anticipated in July.

See Appendix 1 for Gold Springs' CSAMT map and Appendix 2 for Gold Springs' ZTEM map.

About CSAMT

CSAMT (Controlled Source Audio-frequency Magnetotellurics) is a ground-based geophysical survey method from which electrical resistivity information can be obtained from sub-surface down to approximately 1,000 metres. The survey is helpful in identifying zones of both electrically resistive and conductive features that could represent silicification and clay alteration related to epithermal vein systems such as the ones at Gold Springs.

About Gold Springs Resource Corp.

Gold Springs Resource Corp. is focused on the exploration and expansion of the gold and silver resources of its PEA-stage Gold Springs project located on the border of Nevada and Utah, USA. The Company believes Gold Springs has the potential to host multi-million ounces of gold. The project is situated in the prolific Great Basin of Western USA, one of the best mining jurisdictions in the world.

Qualified Person

The Qualified Person on the Gold Springs property is Randall Moore, Executive Vice President of Exploration of Gold Springs Resource Corp. and he has reviewed and approved the content of this press release. Mr. Moore has more than 30 years of mineral exploration experience and is a Professional Geologist and Registered Member of the Society of Mining, Metallurgy, and Exploration. The Qualified Person verified the data disclosed herein for its geological reasonableness, checked all the inputs, and verified the analytical data.

Forward Looking Statements

Certain statements contained herein constitute "forward-looking information" under applicable Canadian securities laws ("forward-looking statements"). Forward-looking statements look into the future and provide an opinion as to the effect of certain events and trends on the business. Forward-looking statements may include words such as "plan", "believe", "would", "continue", "will", "estimate", "promising", and similar expressions. These forward-looking statements are based on current expectations and entail various risks and uncertainties. Actual results may materially differ from expectations if known and unknown risks or uncertainties affect our business or if our estimates or assumptions prove inaccurate. Factors that could cause results or events to differ materially from current expectations expressed or implied by the forward-looking statements, include, but are not limited to, risks of the mineral exploration industry which may affect the advancement of the Gold Springs project, including possible variations in mineral resources, grade, recovery rates, metal prices, capital and operating costs, and the application of taxes; availability of sufficient financing to fund planned or further required work in a timely manner and on acceptable terms; availability of equipment and qualified personnel, failure of equipment or processes to operate as anticipated, changes in project parameters, including water requirements for operations, as plans continue to be refined; regulatory, environmental and other risks of the mining industry more fully described in the Company's Annual Information Form and continuous disclosure documents, which are available on SEDAR at www.sedar.com. The assumptions made in developing the forward-looking statements include: the accuracy of current resource estimates and the interpretation of drill, metallurgical testing and other exploration results; the continuing support for mining by local governments in Nevada and Utah; the availability of equipment and qualified personnel to advance the Gold Springs project; execution of the Company's existing plans and further exploration and development programs for Gold Springs, which may change due to changes in the views of the Company or if new information arises which makes it prudent to change such plans or programs.

Readers are cautioned not to place undue reliance on the forward-looking statements contained in this press release. Except as required by law, the Company assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Unless otherwise indicated, forward-looking statements in this press release describe the Company's expectations as of the date hereof.

Gold Springs Resource Corp. Contact:

Matias Herrero
Chief Executive Officer
info@goldspringsresource.com

Appendix 1 – Gold Springs CSAMT Map

Appendix 2 – Gold Springs ZTEM Map

SOURCE: Gold Springs Resource Corp.

ReleaseID: 594871

CRANBROOK, BC / ACCESSWIRE / June 23, 2020 / Eagle Plains Resources Ltd. (TSXV:EPL), "Eagle Plains") is pleased to announce that 3 additional claims totalling 1,170 hectares have been added to Eagle Plains' 100% owned Olson gold property (the "Property") located 100 km east of La Ronge, northern Saskatchewan. One of the claims was acquired through a 100% purchase from an unrelated third party.

SKRR Exploration ("SKRR") may earn a 75% interest in the 5038ha property by completing exploration expenditures of $3,000,000, making cash payments of $250,000 and issuing 1,000,000 voting class common shares to EPL over a 4 year period.

As previously announced on June 2, 2020, fieldwork on the Property is underway with a DC resistivity / IP geophysical survey recently completed and geological field crews currently on the ground.

Additional Claims

The additional 3 claims increase the Olson property to the south in the central and eastern regions. In the south-central region, the new claim covers a portion of the east-west trending Hartley Shear zone and covers the same prospective volcanic lithological package as the main Carina / Point gold showing, which returned assay values up to 9.8 g/t Au from grab samples, located a further 500m to the north-east.

See the Olson project map here.

2020 Work Program Objectives

Phase One fieldwork has been designed to define targets for a Phase Two diamond drilling program, with planning underway for a Fall, 2020 program. Discovery Geophysics from Saskatoon has completed an 8.3 line-km DC resistivity / IP geophysical survey at the Jena-Juba and Point-Tuscan targets, with preliminary results delivered to the field crews for follow-up during Phase One. Geological fieldwork will include detailed prospecting and mapping, infill soil geochemical sampling and channel sampling of trenches.

Qualified Person

Charles C. Downie, P.Geo., a "qualified person" for the purposes of National Instrument 43-101 – Standards of Disclosure for Mineral Projects and a director of Eagle Plains, has prepared, reviewed, and approved the scientific and technical disclosure in the news release.

About Eagle Plains Resources

Based in Cranbrook, B.C., Eagle Plains continues to conduct research, acquire and explore mineral projects throughout western Canada. The Company is committed to steadily enhancing shareholder value by advancing our diverse portfolio of projects toward discovery through collaborative partnerships and development of a highly experienced technical team. Managements' current focus is to preserve its treasury while advancing its most promising exploration projects. In addition, Eagle Plains continues to seek out and secure high-quality, unencumbered projects through research, staking and strategic acquisitions. Since 2012, Eagle Plains has added to its portfolio a number of new projects exceeding 130,000 ha targeting mainly gold, uranium and base-metals in Saskatchewan, a highly-prospective mining jurisdiction which was recently recognized by the Fraser Institute as the second best place in the world in terms of Investment Attractiveness. Throughout the exploration process, our mission is to help maintain prosperous communities by exploring for and discovering resource opportunities while building lasting relationships through honest and respectful business practices.

Expenditures from 2011-2018 on Eagle Plains-related projects exceed $20M, the majority of which was funded by third-party partners. This exploration work resulted in approximately 30,000 m of diamond-drilling and extensive ground-based exploration work facilitating the advancement of numerous projects at various stages of development.

On behalf of the Board of Directors

"Tim J. Termuende"
President and CEO

For further information on EPL, please contact Mike Labach at
1 866 HUNT ORE (486 8673)
Email: mgl@eagleplains.com or visit our website at http://www.eagleplains.com

Cautionary Note Regarding Forward-Looking Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

SOURCE: Eagle Plains Resources Ltd.

ReleaseID: 594842

NEW YORK, NY / ACCESSWIRE / June 23, 2020 / WIMI Hologram Cloud Inc.("WIMI" or the "Company") (NASDAQ:WIMI),today announced that its wholly-owned Hong Kong subsidiary, WiMi Hologram Cloud Limited ("WiMi Hong Kong")is setting up a joint-venture to explore opportunities in the semiconductor sector.

The Company believes that the application demand of holographic 3D vision in the semiconductor sector is growing rapidly, representing huge market potentials. The establishment of the joint-venture is conducive to the expansion of the semiconductor sector and the rapid integration of market resources. Furthermore, it will facilitate the Company's strategies of extending the holographic 3D vision software from the application layer to the chip field and combining software and hardware through the holographic 3D vision software solution, namely, the strategic derivative upgrade to the semiconductor sector.The Company has accumulated technological capabilities in the field of holographic 3D visual software technology, with hundreds of related patents and software copyrights. In the future,the Company plans to explore opportunities in the semiconductor sector through integrating with IC design companies with core technology advantage, or through establishing are search and development joint venture with chip factory to implement the supply chain upstream of the semiconductor research and development design, technical service and, marketing strategies.

In addition to facilitating the rapid growth of the Company's performance, the Company believes that integration with high-quality semiconductor assets or cooperation with chip companies with strong technology will greatly enhance the Company's competitiveness and consolidate the Company's position in the industry of holographic 3D vision software application, thus supporting the its sustained growth in the medium and long term. At present, many technology companies, such as Qualcomm, Mediatek, Nvidia and other companies, have explored opportunities in artificial intelligence, 5G technology, the Internet of things, and other ecological systems. The market demand for upstream suppliers is no longer limited to simple electronic components or products supply. The market has put forward higher requirements of the suppliers' technical service ability, as well as their ability to provide comprehensive solutions and one-stop value-added services. With the increasing demand for holographic 3D vision-related semiconductor application solutions, the Company plans to combine holographic 3D vision application demand scene to provide corresponding semiconductor solutions to meet the market demand, and promote the application and popularization of holographic 3D vision technology in the semiconductor sector.

WIMI plans to invest in the semiconductor sector,acquire semiconductor assets and cooperate with chip factory in the future, so as to enhance the Company's technical service capability and retain current customers.At the same time, based on higher added value of technology, the Company will continue to improve its revenue capacity. In the next three years, the Company expects that the joint venture will develop relevant operations in the semiconductor sector, and WIMI is expected to embrace a new development.

About WIMI Hologram Cloud Inc.

WiMi Hologram Cloud, Inc.(NASDAQ:WIMI), whose commercial operations began in 2015, operates an integrated holographic AR application platform in China and has built a comprehensive and diversified holographic AR content library among all holographic AR solution providers in China. Its extensive portfolio includes 4,654 AR holographic contents. The company has also achieved a speed of image processing that is 80 percent faster than the industry average. While most peer companies may identify and capture 40 to 50 blocks of image data within a specific space unit, WiMi collects 500 to 550 data blocks.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the Company's annual report on Form 20-F and current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable laws.

For more information, please visit http://ir.wimiar.com/.

Media Contact:

Company: WIMI
Name: Tim Wong
Tele: +86 10 89913328
Email: bjoverseasnews@gmail.com

SOURCE: WIMI

ReleaseID: 594898

TACOMA, WA / ACCESSWIRE / June 23, 2020 / IONIC BRANDS CORP. (CSE:IONC)(OTC PINK:IONKF)(FRA:1B3) ("IONIC BRANDS" or the "Company") is pleased to announce that it has acquired selected assets of WW Agriculture, more specifically the Dabulous economy brand of infused products.

The Company originally entered into a Letter of Intent ("LOI") to acquire WW Agriculture on June 20, 2018. Under the terms of the LOI, the Company's licensed partner, Ionic Washington, began to provide co-manufacturing services including but not limited to the sales and manufacturing of a newly developed brand called Dabulous extracts. While the Company was unable to complete the acquisition of WW Agriculture due to economic challenges in 2019, we continued to co-manufacture and sell the Dabulous products. Since July 2018, the Company has positioned the Dabulous brand as its economy extract brand allowing the Company to service not only the premium consumer segment of the market but the critical economy segment. The Company now has a broader scope of products to capture a more significant share of retail shelf space in the Washington market. The Company will be launching the Dabulous product line in the Oregon market in August 2020. The Company sold 198,036 units and generated $1,759,208 in sales in 2019 from the Dabulous brand.

Full Consideration paid and terms of the Omnibus agreement and bill of sale were as follows:

The Company assumed a note payable with a term of 34 months in the amount of US$195,000, with a cash payment of US$595,000.00.
Cash payment was paid over the course of the co-manufacturing agreement which began on September 1, 2018.
The sale to be consummated upon the full payment of legal fees in the amount of US$12,500 Additionally, the Company purchased US$200,000 in various oil extraction equipment for total consideration paid for the Dabulous Brand of US$989,500.

Ionic Brands Chairman and CEO John P. Gorst commented that, " while we will always remain true to our core brand strategy of premium cannabis products with the Ionic and Zoots brands, we recognized in early 2019 the value of providing a broader range of products priced for a more cost-conscious consumer was important to grow revenue. We are excited about the potential growth of this particular consumer segment."

About IONIC BRANDS CORP.

The Company is focused on building a multi-state consumer-focused cannabis concentrate brand portfolio focusing on the premium and luxury segments. The cornerstone Brand of the portfolio, IONIC, is the #1 vaporizer brand in Washington State and has aggressively expanded throughout the West Coast of the United States. The brand is currently operating in Washington, Nevada, Oregon and California. IONIC BRANDS' strategy is to be the leader of the highest-value segments of the cannabis market and expand nationally.

On behalf of IONIC BRANDS CORP.

John Gorst
Chief Executive Officer & Chairman

For more information visit www.ionicbrands.com or contact:

John Gorst
info@ionicbrands.com
+1.253.248.7927

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The risks are without limitations the price for cannabis and related products will remain consistent and the consumer demand remains strong; availability of financing to the Company to develop the retail locations; retention of key employees and management; changes in State and/or municipal regulations of retail operations and changes in government regulations generally. Important factors that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission and the Alberta Securities Commission.

SOURCE: IONIC BRANDS CORP.

ReleaseID: 594844